Prevalence and characterization of asthma in hospitalized and nonhospitalized patients with COVID-19

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

卷:146

Article

Vu, Thanh Huyen T.^1,2  Mai, Quan³  Yeh, Chen⁴  Muhammad, Lutfiyya N.⁴  Kalhan, Ravi⁵ 

[1] Northwestern Univ, Feinberg Sch Med, Div Allergy & Immunol, Dept Med, Chicago, IL 60611 USA

[2] Northwestern Univ, Feinberg Sch Med, Div Epidemiol, Dept Prevent Med, Chicago, IL 60611 USA

[3] Northwestern Univ, Feinberg Sch Med, Dept Feinberg Informat & Technol, Chicago, IL 60611 USA

[4] Northwestern Univ, Feinberg Sch Med, Dept Prevent Med, Div Biostat, Chicago, IL 60611 USA

[5] Northwestern Univ, Feinberg Sch Med, Dept Med, Div Pulm & Crit Care, Chicago, IL 60611 USA

关键词: COVID-19;    SARS-CoV-2;    asthma;    risk factors;    morbidity;    severity;    corticosteroid;    long-acting beta-agonist;    allergic rhinitis;    rhinosinusitis;   

DOI  :  10.1016/j.jaci.2020.06.010

来源: Elsevier

【 摘 要 】

Background: The Centers for Disease Control and Prevention advises that patients with moderate to severe asthma belong to a high-risk group that is susceptible to severe coronavirus disease 2019 (COVID-19). However, the association between asthma and COVID-19 has not been well-established. Objective: The primary objective was to determine the prevalence of asthma among patients with COVID-19 in a major US health system. We assessed the clinical characteristics and comorbidities in asthmatic and nonasthmatic patients with COVID-19. We also determined the risk of hospitalization associated with asthma and/or inhaled corticosteroid use. Methods: Medical records of patients with COVID-19 were searched by a computer algorithm (March 1 to April 15, 2020), and chart review was used to validate the diagnosis of asthma and medications prescribed for asthma. All patients had PCR-confirmed COVID-19. Demographic and clinical features were characterized. Regression models were used to assess the associations between asthma and corticosteroid use and the risk of COVID-19 related hospitalization. Results: Of 1526 patients identified with COVID-19, 220 (14%) were classified as having asthma. Asthma was not associated with an increased risk of hospitalization (relative risk, 0.96; 95% CI, 0.77-1.19) after adjusting for age, sex, and comorbidities. The ongoing use of inhaled corticosteroids did not increase the risk of hospitalization in a similar adjusted model (relative risk, 1.39; 95% CI, 0.90-2.15). Conclusions: Despite a substantial prevalence of asthma in our COVID-19 cohort, asthma was not associated with an increased risk of hospitalization. Similarly, the use of inhaled corticosteroids with or without systemic corticosteroids was not associated with COVID-19 related hospitalization.

【 授权许可】

Free